Recurrent gene fusions in prostate cancer (original) (raw)

• American Cancer Society: Cancer Facts & Figures 2007 [online] (2007).
• Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Rev. Cancer 8, 268–278 (2008).
  Article CAS Google Scholar
• Denmeade, S. R. & Isaacs, J. T. A history of prostate cancer treatment. Nature Rev. Cancer 2, 389–396 (2002).
  Article CAS Google Scholar
• Loeb, S. & Catalona, W. J. Prostate-specific antigen in clinical practice. Cancer Lett. 249, 30–39 (2007).
  Article CAS PubMed Google Scholar
• Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005). This manuscript reported the discovery of recurrent gene fusions in a majority of prostate cancers.
  Article CAS PubMed Google Scholar
• Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).
  Article CAS Google Scholar
• Ren, R. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Rev. Cancer 5, 172–183 (2005).
  Article CAS Google Scholar
• Goldman, J. M. & Melo, J. V. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451–1464 (2003).
  Article CAS PubMed Google Scholar
• Nowell, P. C. & Hungerford, D. A. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. 25, 85–109 (1960).
  CAS PubMed Google Scholar
• Nowell, P. C. & Hungerford, D. A. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J. Natl Cancer Inst. 27, 1013–1035 (1961). References 9 & 10 were the first reports of the association between a chromosomal aberration (Philadelphia chromosome) and a malignancy (CML).
  CAS PubMed Google Scholar
• Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973).
  Article CAS PubMed Google Scholar
• Rowley, J. D. Chromosome translocations: dangerous liaisons revisited. Nature Rev. Cancer 1, 245–250 (2001).
  Article CAS Google Scholar
• Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). References 13 and 14 established Gleevec/imatinib as a specific inhibitor of BCR–ABL1 in CML.
  Article CAS PubMed Google Scholar
• Mitelman, F., Mertens, F. & Johansson, B. Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Genes Chromosomes Cancer 43, 350–366 (2005).
  Article CAS PubMed Google Scholar
• Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol. Med. (2006).
• Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat. Res. 462, 247–253 (2000).
  Article CAS PubMed Google Scholar
• Mitelman, F., Johansson, B., Mandahl, N. & Mertens, F. Clinical significance of cytogenetic findings in solid tumors. Cancer Genet. Cytogenet. 95, 1–8 (1997).
  Article CAS PubMed Google Scholar
• Mitelman, F., Johansson, B. & Mertens, F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genet. 36, 331–334 (2004). Based on an analysis of prevalence of gene fusions across all cancer types, the authors observed: “Our results support the unorthodox concept that cytogenetic aberrations resulting in deregulated or rearranged genes may be of greater importance as an initial step in epithelial tumorigenesis than generally believed.”
  Article CAS PubMed Google Scholar
• Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nature Rev. Cancer 4, 665–676 (2004).
  Article CAS Google Scholar
• Jeter, J. M., Kohlmann, W. & Gruber, S. B. Genetics of colorectal cancer. Oncology (Williston Park) 20, 269–276; discussion 285–286, 288–289 (2006).
  Google Scholar
• Rowley, P. T. Inherited susceptibility to colorectal cancer. Annu. Rev. Med. 56, 539–554 (2005).
  Article CAS PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Rhodes, D. R. et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9, 443–454 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166–180 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Rhodes, D. R. et al. Mining for regulatory programs in the cancer transcriptome. Nature Genet. 37, 579–583 (2005).
  Article CAS PubMed Google Scholar
• Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1–6 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Oikawa, T. & Yamada, T. Molecular biology of the Ets family of transcription factors. Gene 303, 11–34 (2003).
  Article CAS PubMed Google Scholar
• Sorensen, P. H. et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genet. 6, 146–151 (1994).
  Article CAS PubMed Google Scholar
• Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985).
  Article CAS PubMed Google Scholar
• Taub, R. et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl Acad. Sci. USA 79, 7837–7841 (1982).
  Article CAS PubMed PubMed Central Google Scholar
• Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097–1099 (1984).
  Article CAS PubMed Google Scholar
• Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599 (2007). This paper reported four novel classes of Ets gene fusions in prostate cancer, besides TMPRSS2 , indicating a complex texture of gene fusions in solid cancers
  Article CAS PubMed Google Scholar
• Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006).
  Article CAS PubMed Google Scholar
• Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73–80 (2008).
  Article CAS PubMed Google Scholar
• Hermans, K. G. et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 68, 3094–3098 (2008).
  Article CAS PubMed Google Scholar
• MacDonald, J. W. & Ghosh, D. COPA—cancer outlier profile analysis. Bioinformatics 22, 2950–2951 (2006).
  Article CAS PubMed Google Scholar
• Tibshirani, R. & Hastie, T. Outlier sums for differential gene expression analysis. Biostatistics 8, 2–8 (2007).
  Article PubMed Google Scholar
• Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596–4599 (2007).
  Article CAS PubMed Google Scholar
• Cerveira, N. et al. TMPRSS2_–_ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8, 826–832 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Clark, J. et al. Diversity of TMPRSS2–ERG fusion transcripts in the human prostate. Oncogene 26, 2667–2673 (2007).
  Article CAS PubMed Google Scholar
• Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006).
  Article CAS PubMed Google Scholar
• Perner, S. et al. TMPRSS2–ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882–888 (2007).
  Article PubMed Google Scholar
• Mehra, R. et al. Characterization of TMPRSS2_–_ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hermans, K. G. et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66, 10658–10663 (2006).
  Article CAS PubMed Google Scholar
• Iljin, K. et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66, 10242–10246 (2006).
  Article CAS PubMed Google Scholar
• Lapointe, J. et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 20, 467–473 (2007).
  Article CAS PubMed Google Scholar
• Rajput, A. B. et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 60, 1238–1243 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Soller, M. J. et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45, 717–719 (2006).
  Article CAS PubMed Google Scholar
• Yoshimoto, M. et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8, 465–469 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, J., Cai, Y., Ren, C. & Ittmann, M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66, 8347–8351 (2006).
  Article CAS PubMed Google Scholar
• Liu, W. et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 46, 972–980 (2007).
  Article CAS PubMed Google Scholar
• Melo, J. V. The diversity of BCR–ABL fusion proteins and their relationship to leukemia phenotype. Blood 88, 2375–2384 (1996).
  CAS PubMed Google Scholar
• Lynch, H. T., Smyrk, T. & Lynch, J. F. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int. J. Cancer 69, 38–43 (1996).
  Article CAS PubMed Google Scholar
• Halvarsson, B. et al. Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. J. Clin. Pathol. 60, 781–786 (2007).
  Article CAS PubMed Google Scholar
• Lakhani, S. R. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90, 1138–1145 (1998).
  Article CAS PubMed Google Scholar
• Lakhani, S. R. The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res. 1, 31–35 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Mosquera, J. M. et al. Morphological features of TMPRSS2_–_ERG gene fusion prostate cancer. J. Pathol. 212, 91–101 (2007).
  Article PubMed Google Scholar
• Tu, J. J. et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod. Pathol. 20, 921–928 (2007).
  Article CAS PubMed Google Scholar
• Mehra, R. et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20, 538–544 (2007).
  Article CAS PubMed Google Scholar
• Nami, R. K. et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 6, 40–45 (2007).
  Article Google Scholar
• Nam, R. K. et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 97, 1690–1695 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Attard, G. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253–263 (2007). This paper analysed the prognosis of prostate cancer patients with respect to their TMPRSS2 – ERG rearrangement status and concluded that duplication of the fusion is associated with very poor cause-specific survival (25% survival at 8 years) compared with ERG rearrangement-negative cases (90% survival at 8 years).
  Google Scholar
• Petrovics, G. et al. Frequent overexpression of _ETS_-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005).
  Article CAS PubMed Google Scholar
• Winnes, M., Lissbrant, E., Damber, J. E. & Stenman, G. Molecular genetic analyses of the TMPRSS2_–_ERG and TMPRSS2_–_ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17, 1033–1036 (2007).
  CAS PubMed Google Scholar
• Arora, R. et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100, 2362–2366 (2004).
  Article PubMed Google Scholar
• Mehra, R. et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67, 7991–7995 (2007).
  Article CAS PubMed Google Scholar
• Barry, M., Perner, S., Demichelis, F. & Rubin, M. A. TMPRSS2_–_ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70, 630–633 (2007).
  Article PubMed Google Scholar
• Clark, J. et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27, 1993–2003 (2008).
  Article CAS PubMed Google Scholar
• Mehra, R. et al. Characterization of _TMPRSS2_–ETS gene aberrations in androgen independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Skoda, R. & Prchal, J. T. Lessons from familial myeloproliferative disorders. Semin. Hematol. 42, 266–273 (2005).
  Article CAS PubMed Google Scholar
• Langeberg, W. J., Isaacs, W. B. & Stanford, J. L. Genetic etiology of hereditary prostate cancer. Front. Biosci. 12, 4101–4110 (2007).
  Article CAS PubMed Google Scholar
• Setlur, S. R. et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl Cancer Inst. 100, 915–925 (2008).
  Article CAS Google Scholar
• Bonkhoff, H., Fixemer, T., Hunsicker, I. & Remberger, K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol. 155, 641–647 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913–923 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nature Genet. 39, 41–51 (2007).
  Article CAS PubMed Google Scholar
• Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811–816 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, J. H. et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 67, 8229–8239 (2007).
  Article CAS PubMed Google Scholar
• Lapointe, J. et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 67, 8504–8510 (2007).
  Article CAS PubMed Google Scholar
• Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180–4184 (1999).
  CAS PubMed Google Scholar
• Afar, D. E. et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61, 1686–1692 (2001).
  CAS PubMed Google Scholar
• Vaarala, M. H., Porvari, K., Kyllonen, A., Lukkarinen, O. & Vihko, P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 94, 705–710 (2001).
  Article CAS PubMed Google Scholar
• Mertz, K. D. et al. Molecular characterization of _TMPRSS2_–ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200–206 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Cai, C. et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. 21, 1835–1846 (2007).
  Article CAS PubMed Google Scholar
• Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223–238 (2003).
  Article CAS PubMed Google Scholar
• Tomlins, S. A. et al. Role of the TMPRSS2_–_ERG gene fusion in prostate cancer. Neoplasia 10, 177–188 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci. USA 105, 2105–2110 (2008).
  Article PubMed PubMed Central Google Scholar
• Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci USA 105, 2105–2110 (2008).
  Article PubMed PubMed Central Google Scholar
• Shaffer, D. R. & Pandolfi, P. P. Breaking the rules of cancer. Nature Med. 12, 14–15 (2006).
  Article CAS PubMed Google Scholar
• Crawford, E. D. PSA testing: what is the use? Lancet 365, 1447–1449
• Stamey, T. A. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol. 172, 1297–1301 (2004).
  Article PubMed Google Scholar
• Frankel, S., Smith, G. D., Donovan, J. & Neal, D. Screening for prostate cancer. Lancet 361, 1122–1128 (2003).
  Article PubMed Google Scholar
• Mao, X. et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J. Androl. 10, 467–473 (2008).
  Article CAS PubMed Google Scholar
• Laxman, B. et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8, 885–888 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Laxman, B. et al. A first generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645–649 (2007).
  Article Google Scholar
• Hessels, D. et al. Detection of TMPRSS2–ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13, 5103–5108 (2007).
  Article PubMed Google Scholar
• Huggins, C. & Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 5 (1941).
  Google Scholar
• Huggins, C., Stevens, R. E. & Hodges, C. V. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43 209–222 (1941). References 98 and 99 mark the pioneering work of C. Huggins and C. V. Hodges that introduced androgen ablation therapy as a treatment modality for prostate cancer.
  Article CAS Google Scholar
• Schally, A. V., Kastin, A. J. & Arimura, A. Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies. Fertil. Steril. 22, 703–721 (1971).
  Article CAS PubMed Google Scholar
• Denmeade, S. R. & Isaacs, J. T. in Cancer Medicine 5th edn (eds Bast, R. C. et al.) 765–776 (B. C. Decker, Hamilton, Ontario, 2000).
  Google Scholar
• Steinberg, G. D. & Isaacs, J. T. in Cancer Chemotherapy (eds Hickman, J. A. & Hitton, T. R.) 322–341 (Blackwell Scientific Publications, Oxford, 1993).
  Google Scholar
• Varenhorst, E., Wallentin, L. & Carlstrom, K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand. J. Urol. Nephrol. 16, 31–36 (1982).
  Article CAS PubMed Google Scholar
• Liao, S., Howell, D. K. & Chang, T. M. Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 α-dihydrotestosterone in rat ventral prostate. Endocrinology 94, 1205–1209 (1974).
  Article CAS PubMed Google Scholar
• Maximum androgen blockage in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346, 265–269 (1995).
• Laufer, M., Denmeade, S. R., Sinibaldi, V., Carducci, M. & Eisenberger, M. A. Complete androgen blockade for prostate cancer: What went wrong? J. Urol. 164, 3–9 (2000).
  Article CAS PubMed Google Scholar
• Soda, M. et al. Identification of the transforming EML4_–_ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007). The first report of a recurrent gene fusion in lung cancer.
  Article CAS PubMed Google Scholar
• Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 14 (2007).
  Article CAS Google Scholar
• Korbel, J. O. et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 318, 420–426 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ruan, Y. et al. Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res. 17, 828–838 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Rabbitts, T. H. Chromosomal translocations in human cancer. Nature 372, 143–149 (1994).
  Article CAS PubMed Google Scholar
• Gleissner, B. et al. Leading prognostic relevance of the BCR–ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99, 1536–1543 (2002).
  Article CAS PubMed Google Scholar
• Ribeiro, R. C. et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 70, 948–953 (1987).
  CAS PubMed Google Scholar
• Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1501 (1960).
  Google Scholar
• Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28–37 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Lugo, T. G., Pendergast, A. M., Muller, A. J. & Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079–1082 (1990).
  Article CAS PubMed Google Scholar
• Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990).
  Article CAS PubMed Google Scholar
• Elefanty, A. G., Hariharan, I. K. & Cory, S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9, 1069–1078 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Kelliher, M. A., McLaughlin, J., Witte, O. N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl Acad. Sci. USA 87, 6649–6653 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR–ABL leukemogenesis. Blood 105, 324–334 (2005).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
  Article CAS PubMed Google Scholar
• Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003).
  Article CAS PubMed Google Scholar
• O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
  Article CAS PubMed Google Scholar
• Jhavar, S. et al. Detection of TMPRSS2_–_ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J. Mol. Diagn. 10, 50–57 (2008).
  Article CAS PubMed PubMed Central Google Scholar